Alexander JH - Search Results

1

Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).

Michael Gibson C, Korjian S, Tricoci P, Daaboul Y, Yee M, Jain P, Alexander JH, Steg PG, Lincoff AM, Kastelein JJ, Mehran R, D'Andrea DM, Deckelbaum LI, Merkely B, Zarebinski M, Ophuis TO, Harrington RA. Michael Gibson C, et al. Among authors: alexander jh. Circulation. 2016 Dec 13;134(24):1918-1930. doi: 10.1161/CIRCULATIONAHA.116.025687. Epub 2016 Nov 15. Circulation. 2016. PMID: 27881559 Free PMC article. Clinical Trial.

2

Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?

Akkerhuis KM, Alexander JH, Tardiff BE, Boersma E, Harrington RA, Lincoff AM, Simoons ML. Akkerhuis KM, et al. Among authors: alexander jh. Circulation. 2002 Feb 5;105(5):554-6. doi: 10.1161/hc0502.104278. Circulation. 2002. PMID: 11827918

3

Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes.

Alexander JH, Harrington RA, Bhapkar M, Mahaffey KW, Lincoff AM, Ohman EM, Klootwijk P, Pahlm O, Henden B, Deckers JW, Simoons ML, Califf RM, Wagner GS. Alexander JH, et al. Am J Med. 2003 Dec 1;115(8):613-9. doi: 10.1016/j.amjmed.2003.08.007. Am J Med. 2003. PMID: 14656613

4

Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes.

Rebeiz AG, Roe MT, Alexander JH, Mahaffey KW, Granger CB, Peterson ED, Califf RM, Harrington RA. Rebeiz AG, et al. Among authors: alexander jh. Am J Med. 2004 Jan 15;116(2):119-29. doi: 10.1016/j.amjmed.2003.09.028. Am J Med. 2004. PMID: 14715326 Review.

5

Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.

Waters RE 2nd, Singh KP, Roe MT, Lotfi M, Sketch MH Jr, Mahaffey KW, Newby LK, Alexander JH, Harrington RA, Califf RM, Granger CB. Waters RE 2nd, et al. Among authors: alexander jh. J Am Coll Cardiol. 2004 Jun 16;43(12):2153-9. doi: 10.1016/j.jacc.2003.12.057. J Am Coll Cardiol. 2004. PMID: 15193673 Free article. Review.

6

Incremental prognostic power of single-photon emission computed tomographic myocardial perfusion imaging in patients with known or suspected coronary artery disease.

Borges-Neto S, Shaw LK, Tuttle RH, Alexander JH, Smith WT 4th, Chambless M, Coleman RE, Harrington RA, Califf RM. Borges-Neto S, et al. Among authors: alexander jh. Am J Cardiol. 2005 Jan 15;95(2):182-8. doi: 10.1016/j.amjcard.2004.09.004. Am J Cardiol. 2005. PMID: 15642549

7

Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor.

Becker RC, Alexander JH, Li Y, Robertson T, Kunitada S, Spencer FA, Yang H, Harrington RA. Becker RC, et al. Among authors: alexander jh. J Thromb Thrombolysis. 2004 Dec;18(3):193-7. doi: 10.1007/s11239-005-0345-6. J Thromb Thrombolysis. 2004. PMID: 15815881

8

Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease.

Becker RC, Alexander JH, Dyke C, Huang Y, Saint-Jacques H, Hasselblad V, Harrington RA, Bovill EG; XaNADU-1B Investigators. Becker RC, et al. Among authors: alexander jh. Thromb Res. 2006;117(4):439-46. doi: 10.1016/j.thromres.2005.03.017. Thromb Res. 2006. PMID: 15882894 Clinical Trial.

9

Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes.

Mahaffey KW, Roe MT, Kilaru R, French JK, Alexander JH, Berdan LG, Van De Werf F, Simoons ML, Weaver WD, White HD, Lincoff AM, Kleiman NS, Topol EJ, Harrington RA. Mahaffey KW, et al. Among authors: alexander jh. Am J Cardiol. 2005 Jun 15;95(12):1404-8. doi: 10.1016/j.amjcard.2005.02.005. Am J Cardiol. 2005. PMID: 15950560

10

The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics.

Alexander JH, Ferguson TB Jr, Joseph DM, Mack MJ, Wolf RK, Gibson CM, Gennevois D, Lorenz TJ, Harrington RA, Peterson ED, Lee KL, Califf RM, Kouchoukos NT; PREVENT IV Investigators. Alexander JH, et al. Am Heart J. 2005 Oct;150(4):643-9. doi: 10.1016/j.ahj.2005.05.021. Am Heart J. 2005. PMID: 16209958

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

447 results

Search Page